EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Current Use of Physiologically Based Pharmacokinetic modeling in New Medicinal Product Approvals at EMA

Polly Paul, Pieter J Colin, Flora Musuamba Tshinanu iD, Carolien Versantvoort, Efthymios Manolis, Kevin Blake

Clinical Pharmacology & Therapeutics · 2025-03 · 117 (3) · 808-817

DOI: 10.1002/cpt.3525 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 02.01.2025. Verfasst von Polly Paul und 5 weiteren Autor:innen. Beteiligte Einrichtung: European Medicines Agency, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Drug Approval, Models, Biological, Pharmacokinetics, Drug Development. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Physiologically Based Pharmacokinetic (PBPK) Models are routinely used in drug development and therefore appear frequently in marketing authorization applications (MAAs) to the European Medicines Agency (EMA). For a model to be a key source of evidence for a regulatory decision, it must be considered qualified for the intended use. Advice on the data expected to allow qualification of a PBPK model or platform is provided in the EMA Guideline on the reporting of PBPK modeling and simulation. The present study is an EMA review of the use of PBPK models in submitted MAAs in 2022 and 2023 focussing on the concept of qualification and the reasons why models were not considered qualified. A review of the 95 MAAs with a “full” legal basis approved during these years showed that 25 of them contained PBPK modeling. There were 65 proposed general areas of intended use for PBPK modeling identified across the applications, with the most common being a prediction of drug–drug interactions with enzymes or transporters (69%). Finally, this review showed that most of the models submitted in applications to EMA were not considered qualified for the intended use(s). The reasons identified for this are reported and the need for further EMA guidance, particularly around requirements for qualification of PBPK models, are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalModels, BiologicalPharmacokineticsDrug DevelopmentHumansDrug InteractionsEuropean UnionEuropeComputer Simulation

Autor:innen und Institutionen

  • European Medicines Agency, Amsterdam, The Netherlands.
  • University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Federal Agency for Medicines and Health Products, Brussels, Belgium.
  • University of Namur, Namur, Belgium.
  • Dutch Medicines Evaluation Board, Utrecht, The Netherlands.

ORCID-Profile: Flora Musuamba Tshinanu

Zitieren

APA

Paul, P., Colin, P. J., Musuamba Tshinanu, F., Versantvoort, C., Manolis, E., & Blake, K. (2025). Current Use of Physiologically Based Pharmacokinetic modeling in New Medicinal Product Approvals at EMA. Clinical Pharmacology & Therapeutics, 117(3), 808-817. https://doi.org/10.1002/cpt.3525

Vancouver

Paul P, Colin PJ, Musuamba Tshinanu F, Versantvoort C, Manolis E, Blake K. Current Use of Physiologically Based Pharmacokinetic modeling in New Medicinal Product Approvals at EMA. Clinical Pharmacology & Therapeutics. 2025;117(3):808-817. doi:10.1002/cpt.3525

BibTeX
@article{Paul2025,
  author = {Paul, Polly and Colin, Pieter J and Musuamba Tshinanu, Flora and Versantvoort, Carolien and Manolis, Efthymios and Blake, Kevin},
  title = {Current Use of Physiologically Based Pharmacokinetic modeling in New Medicinal Product Approvals at EMA},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {117},
  number = {3},
  pages = {808--817},
  doi = {10.1002/cpt.3525}
}
Kostenlos starten →